0834 GMT - China's biotech companies' outlicensing trend is sustainable, Jefferies analysts write in a note. The analysts are seeing overwhelming interest and potential incremental fund flows from global healthcare specialists, who are looking into China with the acceleration of biotech outlicensing, they say. Among the companies, Wuxi Biologics mentioned that the higher manufacturing cost in the U.S. will be shouldered by customers, they say. The company's single-asset turnover could reach between two and four times that of its global peers', Jefferies says. Investors are also interested in JD Health for its out-of-pocket branded drug business that could lead to stronger orders, they say. Jefferies's top picks for the sector are Wuxi Biologics, JD Health, Akeso, Duality Biotherapeutics, Hansoh Pharmaceutical and United Imaging. (jiahui.huang@wsj.com; @ivy_jiahuihuang)

(END) Dow Jones Newswires

July 03, 2025 04:34 ET (08:34 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.